ArticlePharmacoEconomics1995
Drug expenditures in a balanced strategy for healthcare policy.
Article in PharmacoEconomics, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The US, like many countries, has turned its public focus onto its healthcare system, with drug prices drawing particular attention. Expenditure trends indicate that drugs do not represent a large portion of the overall healthcare picture; the typical US consumer, however, feels these costs more personally because large portions of outpatient drugs in the US are purchased with out-of-pocket funds. Using data trends for US expenditures, we contrasted projections in the year 2000 under the current US system relative to a strategic policy with full coverage of prescription drugs. Under this proposed scenario, drugs still captured just a small portion of overall healthcare expenditures, but with major shifting to private insurance and government programmes. Thus, as society increasingly views some level of healthcare as a basic human right, effective policies for the healthcare system--including the drug sector--must balance competing regulatory and market pressures.
Indexed as
Identifiers
10155338What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.